Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Protective effect of interferon on the liver solved – targeted treatment approaches available, soon?

06.11.2013
Type I interferons are used for treatment of viral hepatitis because of their antiviral and thus, hepatoprotective effects. Treatment with interferon, however, involves severe adverse effects.

Researchers at the Paul-Ehrlich-Institut have now found the mechanism of how interferon protects the liver. In this context, specific suppressor cells and the balance between the inflammation mediator interleukin-1beta and its inhibitor, the interleukin-1 receptor antagonist play a central role. The findings may provide approaches to a more specific therapy with fewer adverse effects.


Liver histology of mice after treatment with poly(I:C). Control mice (WT) are protected by an interferon-mediated effect, mice without the interferon receptor (IFNAR-/-) develop severe liver damage.

Source: Paul-Ehrlich-Institut

Hepatology reports on the research results in its online prepublication (DOI:10.1002/hep.26915).

Type I interferons are mainly associated with their immunostimulatory, antiviral, and antitumoral effects. However, they also have anti-inflammatory properties. Thus, in patients with a liver inflammation due to a chronic hepatitis-C virus infection, interferon may improve the condition of the liver. This can also be observed when, thanks to treatment, the viral burden is negligible already.

PD (associate professor) Dr Zoe Waibler, head of a temporary research group at the Paul-Ehrlich-Institut (PEI), and co-workers have studied the mechanism which results in this protective effect. For the study not a virus but poly(I:C), an artificial double-stranded RNA which mimics a viral infection, was used. Poly(I:C) was applied to interferon receptor-deficient (IFNAR-deficient) mice and genetically unmodified control mice.

In IFNAR-deficient mice, the treatment with poly(I:C) induced a severe acute liver damage with necrosis, while the control animals were protected. Similarly to human liver inflammations, serum levels of the enzyme alanine aminotransferase also increased upon poly(I:C) treatment of IFNAR-deficient mice, while those of the control mice did not.

In collaboration with Professor Christian Bogdan, Institute of Clinical Microbiology, Immunology, and Hygiene of the University Hospital of Erlangen, the team of PEI researchers identified certain suppressor cells ("myeloid derived suppressor cells", MDSC) as mediators of protection: Upon type I interferon expression, these cells infiltrate the liver, where they convey the protective effect. The team achieved this by switching off the interferon receptor on individual cell types and studying specific surface markers.

Dr Waibler and co-workers were able to show that these suppressor cells influence the balance between the pro- inflammatory cytokine interleukin-1beta (IL-1beta) and its naturally occurring inhibitor, anti-inflammatory interleukin-1 receptor antagonist (IL-1RA) in the liver: For IFNAR-deficient mice, there was a drastic shift toward inflammatory IL-1beta upon poly(I:C) treatment, while for the control mice, the shift occurred in the direction of the anti-inflammatory IL-1RA.

The fact that IL-1beta and IL-1RA indeed induced the inflammatory or protective effects, respectively, in the liver could be proved by Dr Waibler and co-workers by administrating IL-1RA to IFNAR-deficient mice, which prevented the liver damage induced by poly(I:C). Although interferon could not mediate the protective effect here, due to the missing interferon receptor, the downstream effects, normally mediated by interferon, was restored by the administration of IL-1RA. Likewise, liver functions improved in IFNAR-deficient mice if the inflammatory cytokine IL-1beta was neutralized by adding an anti-IL-1beta antibody.

"Interferons have extremely versatile effects by regulating up to 300 genes, thus bringing about a great variety of effects. Only a minor part of them is responsible for this effect on the liver. Maybe an organ-specific therapy would be possible here", explained Dr Waibler with regard to a potential clinical use of these results. Biotechnologically engineered IL-1RA is used in the treatment of rheumatoid arthritis. In addition, there is a genetically engineered monoclonal antibody directed against IL-1beta, which is used in patients with a particular genetic defect.

The PEI researchers also have an explanation for the fact that the suppressor cells in the control mice infiltrate the liver: Based on experimental results, they assume that interferons switch on a particular chemokine in the liver, which attracts the suppressor cells (MDSC).

"Many immunological processes are not fully understood, yet. With our fundamental research, we contribute to developing approaches to therapies that are effective but at the same time cause as few adverse effects as possible", emphasised Professor Cichutek, president of the Paul-Ehrlich-Institut.

Original publication

DOI:10.1002/hep.26915; unedited version

Conrad E, Resch TK, Gogesch P, Kalinke U, Bechmann I, Bogdan C, Waibler Z (2013): Protection against RNA-induced liver damage by myeloid cells requires type I IFN and IL-1 receptor antagonist. Hepatology [Epub ahead of print].

The Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, in Langen near Frankfurt/Main is a senior federal authority reporting to the Federal Ministry of Health (Bundesministerium für Gesundheit, BMG). It is responsible for the research, assessment, and marketing authorisation of biomedicines for human use and veterinary vaccines. Its remit also includes the authorisation of clinical trials and pharmacovigilance, i.e. recording and evaluation of potential adverse effects.

Other duties of the institute include official batch control, scientific advice and inspections. In-house experimental research in the field of biomedicines and life science form an indispensable basis for the varied and many tasks performed at the institute.

The Paul-Ehrlich-Institut, with its roughly 800 members of staff, also has advisory functions nationally (federal government, federal states (Länder)), and internationally (World Health Organisation, European Medicines Agency, European Commission, Council of Europe etc.).

Weitere Informationen:

http://onlinelibrary.wiley.com/doi/10.1002/hep.26915/abstract
Abstract of the publication (accepted, unedited)
http://www.pei.de/EN/information/journalists-press/press-releases/2013/12-protective-effect-interferon-liver-solved.html

Press Release on the Paul-Ehrlich-Institut Website

Dr. Susanne Stöcker | idw
Further information:
http://www.pei.de

More articles from Life Sciences:

nachricht Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel

nachricht The Nagoya Protocol Creates Disadvantages for Many Countries when Applied to Microorganisms
05.12.2016 | Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

IHP presents the fastest silicon-based transistor in the world

05.12.2016 | Power and Electrical Engineering

InLight study: insights into chemical processes using light

05.12.2016 | Materials Sciences

High-precision magnetic field sensing

05.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>